BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has announced the pricing on March 7, 2023 of an underwritten public offering of 8,823,530 shares of its common stock at a public offering price of US$17.00 per share, before deducting underwriting discounts and commissions. In addition, BridgeBio has granted […]
The post Latham & Watkins Advises on BridgeBio Pharma’s Public Offering of Common Stock appeared first on Legal Desire.